Latest news and press releases about Senseonics Holdings, Inc. (SENS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices.
Price
| Price | $9.06 |
| Market Cap | $379M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 5.75 |
| EV / EBITDA | -3.69 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -113.21% |
| Return on Invested Capital | -66.72% |
| Return on Assets | -54.73% |
| Gross Margin | 54.87% |
| Operating Margin | -223.22% |
| Net Margin | -225.34% |
Related companies: ACRS · CAPR · CERS · CVRX · MASS · NNOX · NPCE
Explore sector: Healthcare · Medical - Devices
More sections of SENS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks